Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Trial Profile

A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms POSEIDON
  • Sponsors Incyte Biosciences International
  • Most Recent Events

    • 12 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to revisiting the availability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward
    • 30 Nov 2018 Planned initiation date changed from 15 Nov 2018 to 31 Dec 2018.
    • 03 Oct 2018 Planned initiation date changed from 15 Sep 2018 to 15 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top